Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

BIOMERICA INC

BMRA

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.

Last trade $1.29
Day change -$0.03 (-2.27%)
Day range $1.14 – $1.35
Volume 13,472
Market cap $6M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.07M
Price / earnings
—
Price / book
1.66×
Price / sales
1.4×
EV / sales
0.77×
EV / EBITDA
-0.62×

Profitability

Earnings per share
-$1.09
Return on assets
-62.06%
Return on equity
-137.31%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.91×
Quick ratio
1.33×
Cash ratio
0.96×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BMRA, quarterly periods
Line itemQ1 FY2027 Aug 31, 2026Q4 FY2026 May 31, 2026Q3 FY2026 Feb 28, 2026Q2 FY2026 Nov 30, 2025Q1 FY2026 Aug 31, 2025Q4 FY2025 May 31, 2025Q3 FY2025 Feb 28, 2025Q2 FY2025 Nov 30, 2024
Revenue$1.27M$875K$987K$1.21M$1.38M$749K$1.12M$1.64M
Cost of revenue$1.16M$946K$1.03M$1.16M$956K$993K$1.1M$1.2M
Gross profit$103K-$71K-$44K$51K$424K-$244K$19K$437K
Selling, general and administrative$1.12M$1.26M$1.08M$1.23M$1.33M$1.07M$1.01M$1.17M
Research and development$206K$205K$178K$193K$212K$252K$217K$257K
Total operating expenses$1.33M$1.46M$1.25M$1.42M$1.54M$1.32M$1.23M$1.43M
Operating income-$1.23M-$1.53M-$1.3M-$1.37M-$1.12M-$1.56M-$1.21M-$993K
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$1.23M-$1.14M-$1.3M-$1.32M$5K-$1.54M-$1.17M-$953K
Income taxes$6K$6K$8K$5K$3K$5K-$4K-$3K
Net income-$1.23M-$1.15M-$1.31M-$1.32M$2K-$1.54M-$1.16M-$950K
Net income attributable to common shareholders-$1.23M-$1.15M-$1.31M-$1.32M$2K-$1.54M-$1.16M-$950K
EBITDA-$1.21M-$1.52M-$1.28M-$1.35M-$1.1M-$1.54M-$1.19M-$971K
Basic earnings per share-$0.37-$0.37-$0.44-$0.45$0.00-$0.61-$0.48-$0.44
Diluted earnings per share-$0.37-$0.37-$0.44-$0.45$0.00-$0.61-$0.48-$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Biomerica reported Q2 FY2026 results with net sales of $1.21M (down from $1.64M YoY) as the company transitions from legacy products to higher-margin diagnostic offerings. Key developments include a partnership with Henry Schein for inFoods® IBS commercialization, launch of an AI-backed Trigger Food Navigator tool, CMS establishment of a $300 Medicare reimbursement rate for inFoods® IBS, and Egyptian Drug Authority approval of the company's screening test portfolio. Operating expenses declined 4% YoY to $2.96M for the six-month period, and working capital improved by 14.7%.

GlobeNewswire Inc.

Biomerica Reports Fiscal 2025 Year End Results

Biomerica reported modest financial performance with $5.3 million in net sales, reduced operating expenses by $1.3 million, and improved operating loss by 19%. The company focused on strategic growth in diagnostic tests, particularly inFoods® IBS, and expanded international market presence.

GlobeNewswire Inc.

Biomerica Reports Fiscal 2024 Year End Results

Biomerica reported a modest 1% increase in total revenue for fiscal year 2024, with a 5% increase in core revenue excluding COVID-19 tests. The company implemented a significant cost-savings plan and reduced its net loss by 15%. Key milestones included FDA clearance for its Hp Detect Stool Antigen ELISA test and progress in the inFoods IBS pilot program.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 21, 20251-for-8reverse split